Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 6Neoplasms 3Neoplasm Metastasis 3Neuroendocrine Tumors 2Neuroectodermal Tumors, Primitive 2Glioblastoma 2Carcinoma, Renal Cell 2Uterine Neoplasms 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Perivascular Epithelioid Cell Neoplasms 1Pancreatic Neoplasms 1Malignant Solid Tumour 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Hamartoma Syndrome, Multiple 1Gliosarcoma 1Endometrial Neoplasms 1Castration-resistant Prostate Cancer 1Castrate-resistant Prostate Cancer 1Carcinoma, Transitional Cell 1Breast Diseases 1Brain Neoplasms 1Angiomyolipoma 1Advanced Solid Tumor 1

Interventions

Gemcitabine 677130-nm albumin-bound paclitaxel 197Fluorouracil 184Oxaliplatin 173Albumin-Bound Paclitaxel 151Capecitabine 137Leucovorin 129Irinotecan 111Radiotherapy 95Taxes 83pembrolizumab 80Cisplatin 71Erlotinib Hydrochloride 69Radiosurgery 67Nivolumab 56Bevacizumab 54Drug Therapy 52Cyclophosphamide 48Magnetic Resonance Spectroscopy 45folfirinox 42Docetaxel 41Cetuximab 40irinotecan sucrosofate 36Specimen Handling 36S 1 (combination) 36Biopsy 30Radiation 29Paclitaxel 29Ipilimumab 27Surgical Procedures, Operative 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pancreatic Neoplasms × dactolisib × Clear all
NCT01337765 2020-10-09

Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients

Pfizer

Phase 1 Completed
29 enrolled
BreastGastrointestinal

Pancreatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡